

PRIOR AUTHORIZATION REQUEST

<u>Austedo</u>

Patient	: Information:			
Name:				
Membe	er ID:			
Addres	ss:			
City, St	tate, Zip:			
Date of	f Birth:			
Prescri	iber Information:			
Name:				
NPI:				
Phone	Number:			
Fax Nu	ımber			
Addres				
	tate, Zip:			
, ,	·····			
	sted Medication			
Rx Nar				
Rx Stre				
Rx Qua				
	quency:			
Rx Rou				
	stration:			
Diagno	sis and ICD Code:			
prescribe quantities Upon re	ed a medication for you s can be provided. Plea ceipt of the completed ON A: Please no	efit requires that we review certain requests for coverage with the repatient that requires Prior Authorization before benefit coverage of ase complete the following questions then fax this form to the toll-fred form, prescription benefit coverage will be determined based on the that supporting clinical documentation is required.	r coverage of ee number lis on the plar	f additiona sted below n's rules.
1	Is the patient great [If no, no further qu	er than or equal to 18 year(s) of age? uestions.]	Yes	No
2	[] Tardive dyskines	ion or diagnosis? ed with Huntington's disease (If checked, go to 3) ia (If checked, go to 8) I, no further questions)		
3	Is this medication be [If no, no further qu	peing prescribed by, or in consultation with, a neurologist? sestions.]	Yes	No
4	Is this request a co	ntinuation of therapy?	Yes	No

If you have any questions, call: 1-888-258-8250

PRV 07.02.25.2

PRIOR AUTHORIZATION REQUEST

	[If yes, skip to question 15.]		
5	Has the patient tried at least ONE other agent for at least 3 months? [Note: Examples of other agents include tetrabenazine with dose optimization, amantadine, and riluzole.] [If yes, skip to question 7.]	Yes	No
6	Does the patient have a documented intolerance to at least TWO other agents? [Note: Examples of other agents include tetrabenazine with dose optimization, amantadine, and riluzole.] [If no, no further questions.]	Yes	No
7	Is the patient's diagnosis confirmed by genetic testing (for example, an expanded HTT CAG repeat sequence of at least 36)? [If yes, skip to question 13.] [If no, no further questions.]	Yes	No
8	Is this medication being prescribed by, or in consultation with, a neurologist or psychiatrist? [If no, no further questions.]	Yes	No
9	Is the request a continuation of therapy? [If yes, skip to question 14.]	Yes	No
10	Has the patient tried at least ONE other agent for at least 3 months OR has a documented intolerance? [Note: Examples of other agents include tetrabenazine with dose optimization.] [If no, no further questions.]	Yes	No
11	Does the patient have persistent symptoms of moderate or severe tardive dyskinesia indicated on the Abnormal Involuntary Movement Scale (AIMS)? [If no, no further questions.]	Yes	No
12	Does the patient have any ONE of the following: A) Untreated psychiatric illness; B) Score of greater than or equal to 11 on the depression subscale of the Hospital Anxiety and Depression Scale (HADS); C) A history of suicidal thoughts or behavior; D) Hepatic impairment; E) Concurrent use of monoamine oxidase inhibitors, reserpine, tetrabenazine, or valbenazine? [If yes, no further questions.]	Yes	No
13	Does the dose of the requested medication exceed FDA approved label dosing for the indication? [No further questions.]	Yes	No
14	Has documentation been provided to show that the patient's symptoms have improved by a decreased Abnormal Involuntary Movement Scale (AIMS) score from baseline? [If no, no further questions.]	Yes	No

If you have any questions, call: 1-888-258-8250



PRIOR AUTHORIZATION REQUEST

Has the patient been established on the requested medication for at least 3 months with a clinically significant response, as determined by the prescriber?

Yes

No

Please document the diagnoses, symptoms, and/or any other information important to this review:

SECTION B: Physician Signature

PHYSICIAN SIGNATURE

DATE

FAX COMPLETED FORM TO: 1-833-896-0656

Disclaimer: An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

Confidentiality: The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.

If you have any questions, call: 1-888-258-8250